Clinical Trials Logo
  1. Home
  2. HIV Infections
  3. NCT05536466
  4. Details
NCT05536466 Clinical Trial

The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine

HIV Infections Clinical Trial

— LABRADOR  

Official title:
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05536466
Other study ID # LABRADOR
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 30, 2022
Est. completion date August 1, 2023

Study information
Verified date September 2022
Source Radboud University Medical Center
Contact Leena Zino
Phone 0031243611111
Email leena.zino@radboudumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

a multicentre phase IV study to collect evidence that a doravirine-based regimen can be safely and effectively administered to virologically suppressed HIV-infected patients undergoing bariatric suregery.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 8
Est. completion date August 1, 2023
Est. primary completion date July 23, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - HIV-infected - VL suppressed <40c/ml for at least 6 months, blips are allowed - planned to have bariatric surgery (gastric bypass or gastric sleeve) - Able to sign informed consent - Age > or equal to 18 years - Using doravirine for at least 4 weeks prior to BS with VL < 40 copies/mL prior to the surgery Exclusion Criteria: - History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study or interfere with the subject's participation - Requires or is anticipated to require any of the prohibited medications known to contradict/interact with doravirine - Has significant hypersensitivity or other contraindication to doravirine - Creatinine clearance <40 ml/min - Severe liver dysfunction (Diagnosed liver cirrhosis: Child-Pugh C) - Pregnancy or planning to be pregnant during first 6 months postbariatric surgery.

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• bariatric surgery
bariatric surgery

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Radboud University Medical Center

Outcome
Type Measure Description Time frame Safety issue
Primary AUC of doravirine area under the curve, doravirine 24 hours
Secondary adverse events adverse events 24 weeks
Secondary HIV viral load HIV viral load 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2
Completed NCT01968551 - Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults Phase 3